Indication
HER2-positive Circulating Tumor Cells
1 clinical trial
2 products
Clinical trial
DETECT III - A Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients With Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor CellsStatus: Completed, Estimated PCD: 2022-01-01
Product
Lapatinib